Examen
Page URL: https://www.bionews.org.uk/page_95300

Progesterone does not help women with recurrent miscarriages

30 November 2015
Appeared in BioNews 830

Progesterone supplementation in the first trimester of pregnancy does not improve outcomes for women with unexplained recurrent miscarriages, according to a large clinical trial.

The PROMISE trial conducted in the UK and Netherlands included 826 women aged between 18–39 years with a history of recurrent miscarriages. Participants received either twice-daily vaginal preparations of 400 mg progesterone or placebo from shortly after conception up to the 12th week of pregnancy. Neither participants nor doctors knew which they were receiving.

During the study, almost two-thirds of participants gave birth at 24 weeks gestation or later. With a live birth rate of 65.8 percent and 63.3 percent in the progesterone therapy and placebo group, respectively, the researchers concluded that administration of progesterone does not significantly affect the rate of live births. This was true regardless of the women's age, ethnicity, medical history and pregnancy history.

Progesterone is produced naturally in early pregnancy by the corpus luteum in the ovary, and is essential to help achieve and maintain early pregnancy. For this reason, many studies have sought to evaluate the effectiveness of supplementation for reducing the risk of recurrent miscarriages.

After 60 years of uncertainty, the researchers say the PROMISE trial, which is published in the New England Journal of Medicine, should provide a conclusive answer.

Lead author, Professor Arri Coomarasamy, from the University of Birmingham, commented, 'We had hoped, like many people, that this research would confirm progesterone as an effective treatment. Though disappointing, it does address a question that has remained unanswered since progesterone was first proposed as a treatment back in 1953.'

Contrary to the results of this trial, previous findings from a Cochrane analysis of four small studies support the use of first-trimester progesterone therapy. However, these trials had 'substantive methodological limitations', the authors of the current study state.

Professor Coomarasamy said, 'Fortunately, there are a number of other positives that we can take from the trial as a whole.' For example, no statistical difference in adverse outcomes (such as congenital abnormalities) between the groups were reported. This is reassuring for women who take progesterone for fertility treatment purposes or those involved in other trials.

'It may well be that progesterone supplements have other uses, such as preventing miscarriage in women with early pregnancy bleeding, so it's not the end of the road,' Professor Coomarasamy added. 

SOURCES & REFERENCES
A Randomized Trial of Progesterone in Women with Recurrent Miscarriages
NEJM |  26 November 2015
Progesterone Does Not Prevent Recurrent Miscarriage
MedScape |  25 November 2015
Progesterone May Not Help Women With History of Miscarriages, Study Finds
New York Times |  25 November 2015
Progesterone Safe But Not Helpful for Preventing Miscarriages
MedPageToday |  25 November 2015
Progesterone supplements do not improve outcomes for recurrent miscarriages
Eurekalert (press release) |  25 November 2015
The PROMISE trial: a clear result
The Miscarriage Association |  25 November 2015
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 May 2016 - by Dr Jane Currie 
Researchers have identified a protein that may help developing embryos stick to the uterus...
14 March 2016 - by Dr Lanay Griessner 
Recurrent miscarriage could be caused by a lack of resident stem cells in the lining of the womb, according to a study...
9 November 2015 - by Dr Norman Shreeve 
In recent years a range of treatments aimed at suppressing uterine natural killer activity have sprung up, but this has no scientific rationale and can have significant and dangerous side effects...
28 August 2012 - by John Brinsley 
Women who repeatedly reject pregnancies may be 'too good' at carrying, research indicates...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.